Loading...
NEJM Journal Watch has brought you coverage of study findings presented at the European Society of Cardiology's annual meeting. Here is a compilation of our coverage, listed by title of NEJM Journal Watch summary, with the study article's first author in parentheses. (Your NEJM Journal Watch subscription is required.)
A Polypill Strategy for the Secondary Prevention of Cardiovascular Disease (Castellano JM)
Fixed-dose combination pills containing aspirin, a statin, and an ACE inhibitor improved outcomes in older patients with recent myocardial infarction. Read the summary.
No Survival Benefit of Percutaneous Revascularization for Ischemic LV Dysfunction (Perera D)
In the REVIVED trial, survival, hospitalization, and left ventricular systolic function were no better with an invasive than a conservative strategy during intermediate-term follow-up. Read the summary.
Vitamin K Antagonists Supported in Patients with Atrial Fibrillation and Rheumatic Disease (Connolly SJ)
More cardiovascular events and deaths occurred among rivaroxaban users than in VKA users during a 3-year follow-up. Read the summary.
Another SGLT-2 Inhibitor Shows Promise for Heart Failure (Solomon SD)
The DELIVER trial found benefit with dapagliflozin in patients with preserved ejection fraction. Read the summary.
SGLT-2 Inhibitors for Heart Failure — Including Heart Failure with Preserved Ejection Fraction (Vaduganathan M)
A meta-analysis shows these agents to be effective across a spectrum of ejection fractions. Read the summary.
Treating Acute Volume Overload of Heart Failure with Acetazolamide (Mullens W)
In patients hospitalized for acute heart failure exacerbation receiving loop diuretics, acetazolamide improved decongestion compared with placebo. Read the summary.
Does Functional Testing After PCI Improve Outcomes in High-Risk Patients? (Park D-W)
No, based on 2-year outcomes in a randomized study of routine testing at 1 year. Read the summary.
Population-Based Cardiovascular Screening in Older Men Shows No Mortality Benefit (Lindholt JS)
Men ages 65 to 74 offered comprehensive screening with intensive follow-up had similar mortality as controls. Read the summary.
ARB and Beta-Blocker Effects in Marfan Syndrome (Pitcher A)
Both angiotensin-receptor blockers and beta-blockers slowed the rate of increase in aortic-root size, according to a meta-analysis of individual-level randomized-trial data. Read the summary.
Risk for Muscle Pain or Weakness with Statins Is Slight (Cholesterol Treatment Trialists' Collaboration)
A rigorous meta-analysis showed a barely significant association of mild muscle symptoms with statins in the first year after initiation. Read the summary.
Autoimmune Diseases Linked with Incident Cardiovascular Disease (Conrad N)
A large, population-based study from the UK documented elevated CVD risk in people with a broad range of autoimmune diseases. Read the summary.
A New Type of Subcutaneous ICD (Friedman P)
A subcutaneous implantable cardioverter–defibrillator whose single lead is inserted substernally performed well in a nonrandomized trial. Read the summary.